TNF-alpha Variant Fusion Molecules

USPTO published patent application US20260092092A1 disclosing novel TNF-alpha variant fusion molecules and methods of using them for therapeutic applications. The application covers compositions comprising TNF-alpha variants fused to other molecules, with potential therapeutic uses in treating inflammatory and immune-related conditions. CPC classifications include C07K 14/525, A61K 38/191, and C12N 15/63.

Patent applicants and biotechnology companies should review this publication for potential prior art implications against existing or planned programs involving TNF-alpha targeted therapeutics. IP professionals should update patent landscape analyses to include this application. No compliance deadlines or penalties apply to this publication.